347.14 +0.12 (0.03%)
After hours: 6:25PM EDT
|Bid||347.04 x 1000|
|Ask||354.88 x 1200|
|Day's Range||341.92 - 347.76|
|52 Week Range||249.17 - 388.67|
|PE Ratio (TTM)||24.64|
|Earnings Date||Oct 23, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||389.20|
Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest moves.
Biotechnology is considered one of the most dynamic and profitable sectors, where investment in research and development is necessary for survival. Biogen Inc. (BIIB) is one of the leading players in this sector, with a proven track record in neurological and neurodegenerative diseases. The company has a strong portfolio of drugs catering to diseases like multiple sclerosis, Alzheimer's, dementia and neuromuscular disorders.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to start learning about core conceptsRead More...
Federal prosecutors are probing whether big drugmakers including Sanofi, Gilead Sciences and Biogen potentially violated laws by providing free services to doctors and patients.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company, is developing medicines for the treatment of life-altering central nervous system disorders like major depressive disorder, Parkinson’s disease, postpartum depression, and others.
Biogen Inc.'s ( BIIB) stock has largely disappointed investors for more than three years since it fell off its high in 2015. Earnings and revenue estimates for 2018 have increased in recent months. The company beat second-quarter estimates in July and offered better guidance. As a result, analysts now forecast earnings growth of 7% for the quarter on revenue growth of 8%.
The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works
On Monday, GuruFocus' High Quality Screener listed three biotechnology companies that offer good potential ahead of the fourth quarter: Biogen Inc. (BIIB), Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NVO). Warning! GuruFocus has detected 4 Warning Signs with ORCL. Berkshire Hathaway Inc. (BRK-A)(BRK-B) CEO Warren Buffett (Trades, Portfolio) has stressed several times that key investing criteria include predictable earnings and strong economic moat.
Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.
Its net loss per share was $0.17 in the second quarter of 2017. Six of them have given Sangamo stock a “buy” or higher rating, and one has rated it a “hold.” The mean rating for Sangamo stock is 1.71 with a target price of $27.83, implying an upside potential of 89.32% over its closing price of $14.70 on September 11. In comparison, peers Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD) have mean ratings of 2, 1.78, and 2.15, respectively, and target prices of $389.20, $119.35, and $87.87, respectively.
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
CHARM study will evaluate IV glibenclamide for the prevention and treatment of severe cerebral edema in LHI, one of the most severe types of ischemic stroke with limited treatment options Prior studies ...
Here's a look at the Boston biotech news you missed during your summer vacation: Alnylam gets historic FDA approval for first drug Cambridge's Alnylam Pharmaceuticals (Nasdaq: ALNY) received FDA approval for its first drug on Aug. 10, a first-ever treatment for a rare genetic disease that uses RNA interference to silence genes. The drug treats hereditary ATTR amyloidosis, which causes the liver to protein abnormal proteins that impede nervous system and organ functions. Marketed under the name Onpattro, it's the first RNA interference drug to be approved by the FDA.
The biotech sector performed well in August, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) up almost 3.5% this week alone. Research by Raymond James indicates that in just the past week, biotech ...
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017, reflecting a ~17% YoY (year-over-year) growth. It reported net revenues of $746.3 million in the first half of 2018 compared to $621.2 million in the first half of 2017, reflecting a ~2% YoY growth.
On August 30, BioMarin Pharmaceutical (BMRN) stock closed at $99.26, which is ~7% below its 52-week high of $106.20 on August 2. It hit its 52-week low of $75.81 on April 6.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on Aug. 28) Abbott Laboratories (NYSE: ABT ) Affimed NV (NASDAQ: AFMD )(announced ...
The U.S. Moat Index posted strong performance again in July, and by the end of the month, its year-to-date results overtook the S&P 500 Index despite being underweight to the information technology sector. The U.S. Moat Index has been overweight healthcare companies for some time now as a result of the valuation dynamics in the sector. That positioning paid off in July with the top five performing constituents all coming from the sector.
CAMBRIDGE, Mass., Aug. 28, 2018-- Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension Phase 1 b study of aducanumab, an investigational treatment for ...